(BMRN) Biomarin Pharmaceutical - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09061G1013

Enzyme Replacement, Growth Modulator, Gene Therapy, Small Molecule

Stock: Biotechnology
Age 26.5y

MCap 10,818m
Avg Vol 2.17M (128M USD)

Beta 0.737
Volatility 30.86%

EPS (Earnings per Share)

EPS CAGR: -30.01%
EPS Trend: 49.4%

Last SUE: -2.06
Qual. Beats: 0

Revenue

Rev. CAGR: 15.66%
Rev. Trend: 97.2%

Last SUE: -0.13
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	30.9%
Value at Risk 5%th	45.4%
Relative Tail Risk	-10.62%

Reward TTM
Sharpe Ratio	-0.21
Alpha	-20.64
CAGR/Max DD	-0.38

Character TTM
Hurst Exponent
Beta	0.737
Beta Downside	0.906

Drawdowns 3y
Max DD	56.12%
Mean DD	34.37%
Median DD	29.97%

Description: BMRN Biomarin Pharmaceutical January 02, 2026

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a U.S.-based biotech that focuses on developing and commercializing therapies for rare, life-threatening diseases across North America, Europe, Latin America, the Middle East, and the Asia-Pacific.

The firm’s marketed portfolio includes VIMIZIM (MPS IV A), VOXZOGO (achondroplasia), NAGLAZYME (MPS VI), PALYNZIQ (phenylketonuria), BRINEURA (Batten disease), ALDURAZYME (MPS I), KUVAN (PKU), and ROCTAVIAN (severe hemophilia A). Its pipeline features BMN 333 (long-acting CNP for growth disorders), BMN 349 (oral therapy for α1-antitrypsin deficiency-related liver disease), and BMN 351 (antisense oligonucleotide for Duchenne muscular dystrophy).

In 2023 BioMarin generated approximately $2.1 billion in revenue, with VIMIZIM and VOXZOGO together accounting for roughly 45 % of sales, while the company posted a net loss of $215 million, reflecting high R&D spend and amortization of acquisition-related intangibles. The rare-disease sector is currently benefitting from favorable orphan-drug pricing policies and a CAGR of ~10 % in global orphan-drug sales, but it also faces increasing payer scrutiny on price sustainability.

For analysts looking to deepen their quantitative assessment, the ValueRay platform offers a consolidated view of BioMarin’s valuation metrics and peer-group benchmarks that can help surface any pricing anomalies.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income: 520.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 6.53 > 1.0
NWC/Revenue: 98.78% < 20% (prev 85.04%; Δ 13.74% < -1%)
CFO/TA 0.12 > 3% & CFO 914.0m > Net Income 520.4m
Net Debt (-653.4m) to EBITDA (772.4m): -0.85 < 3
Current Ratio: 4.83 > 1.5 & < 3
Outstanding Shares: last quarter (192.0m) vs 12m ago -2.59% < -2%
Gross Margin: 81.32% > 18% (prev 0.79%; Δ 8053 % > 0.5%)
Asset Turnover: 42.78% > 50% (prev 40.18%; Δ 2.60% > 0%)
Interest Coverage Ratio: 64.46 > 6 (EBITDA TTM 772.4m / Interest Expense TTM 10.7m)

Altman Z'' (< 1.1 .. > 2.6) 3.46

A: 0.40 (Total Current Assets 3.85b - Total Current Liabilities 798.4m) / Total Assets 7.61b
B: 0.03 (Retained Earnings 200.8m / Total Assets 7.61b)
C: 0.10 (EBIT TTM 689.6m / Avg Total Assets 7.23b)
D: 0.10 (Book Value of Equity 155.7m / Total Liabilities 1.56b)
Altman-Z'' Score: 3.46 = A

ValueRay F-Score (Strict, 0-100) 79.63

1. Piotroski: 8.0pt
2. FCF Yield: 8.37%
3. FCF Margin: 26.87%
4. Debt/Equity: 0.10
5. Debt/Ebitda: -0.85
6. ROIC - WACC: 0.19%
7. RoE: 8.84%
8. Revenue Trend: 97.24%
9. EPS Trend: 49.37%

What is the price of BMRN shares?

As of January 22, 2026, the stock is trading at USD 56.77 with a total of 2,066,380 shares traded.
Over the past week, the price has changed by +1.23%, over one month by -4.23%, over three months by +5.50% and over the past year by -9.21%.

Is BMRN a buy, sell or hold?

Biomarin Pharmaceutical has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy BMRN.

Strong Buy: 16
Buy: 7
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BMRN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	90.7	59.8%
Analysts Target Price	90.7	59.8%
ValueRay Target Price	54.7	-3.7%

BMRN Fundamental Data Overview January 22, 2026

P/E Trailing = 20.9331
P/E Forward = 10.7875
P/S = 3.4964
P/B = 1.7861
P/EG = 0.4332
Revenue TTM = 3.09b USD
EBIT TTM = 689.6m USD
EBITDA TTM = 772.4m USD
Long Term Debt = 596.7m USD (from longTermDebt, last quarter)
Short Term Debt = 23.1m USD (from shortTermDebt, last fiscal year)
Debt = 596.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -653.4m USD (from netDebt column, last quarter)
Enterprise Value = 9.94b USD (10.82b + Debt 596.7m - CCE 1.48b)
Interest Coverage Ratio = 64.46 (Ebit TTM 689.6m / Interest Expense TTM 10.7m)
EV/FCF = 11.95x (Enterprise Value 9.94b / FCF TTM 831.4m)
FCF Yield = 8.37% (FCF TTM 831.4m / Enterprise Value 9.94b)
FCF Margin = 26.87% (FCF TTM 831.4m / Revenue TTM 3.09b)
Net Margin = 16.82% (Net Income TTM 520.4m / Revenue TTM 3.09b)
Gross Margin = 81.32% ((Revenue TTM 3.09b - Cost of Revenue TTM 577.9m) / Revenue TTM)
Gross Margin QoQ = 81.95% (prev 81.82%)
Tobins Q-Ratio = 1.30 (Enterprise Value 9.94b / Total Assets 7.61b)
Interest Expense / Debt = 0.43% (Interest Expense 2.58m / Debt 596.7m)
Taxrate = 21.21% (114.9m / 541.8m)
NOPAT = 543.4m (EBIT 689.6m * (1 - 21.21%))
Current Ratio = 4.83 (Total Current Assets 3.85b / Total Current Liabilities 798.4m)
Debt / Equity = 0.10 (Debt 596.7m / totalStockholderEquity, last quarter 6.06b)
Debt / EBITDA = -0.85 (Net Debt -653.4m / EBITDA 772.4m)
Debt / FCF = -0.79 (Net Debt -653.4m / FCF TTM 831.4m)
Total Stockholder Equity = 5.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.20% (Net Income 520.4m / Total Assets 7.61b)
RoE = 8.84% (Net Income TTM 520.4m / Total Stockholder Equity 5.88b)
RoCE = 10.64% (EBIT 689.6m / Capital Employed (Equity 5.88b + L.T.Debt 596.7m))
RoIC = 8.39% (NOPAT 543.4m / Invested Capital 6.48b)
WACC = 8.20% (E(10.82b)/V(11.41b) * Re(8.63%) + D(596.7m)/V(11.41b) * Rd(0.43%) * (1-Tc(0.21)))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.05%
[DCF Debug] Terminal Value 80.62% ; FCFF base≈619.2m ; Y1≈763.8m ; Y5≈1.30b
Fair Price DCF = 113.4 (EV 21.14b - Net Debt -653.4m = Equity 21.79b / Shares 192.1m; r=8.20% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 49.37 | EPS CAGR: -30.01% | SUE: -2.06 | # QB: 0
Revenue Correlation: 97.24 | Revenue CAGR: 15.66% | SUE: -0.13 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.31 | Chg30d=+0.052 | Revisions Net=+1 | Analysts=13
EPS next Year (2026-12-31): EPS=5.21 | Chg30d=-0.020 | Revisions Net=+1 | Growth EPS=+54.6% | Growth Revenue=+6.9%

Additional Sources for BMRN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle